Chemotherapy of advanced XXXX : Eastern Cooperative Oncology Group experience.

@entity1 @entity632 @entity189 @entity1500 @entity418 @entity3 @entity1499 @entity1487
In a Phase II study, @entity1 with measurable metastatic or recurrent @entity418 randomly received after @entity632 (ADR), 60 mg/M2 I.V. q three weeks, or @entity1499 ( @entity1500 ), 40 mg/M2 I.V. q one week, or @entity1487 ( @entity1487 ), 500 mg/m2 I.V. x 5 days q five weeks. Objective partial response rates for 72 @entity1 were 5% for ADR (one of 20), 12% for @entity1500 (three of 26), and 15% for @entity1487 (four of 26). There were no complete responses. Median duration of response was 13 weeks. Median survival was 14 weeks (eight weeks for ADR, 14 weeks for @entity1500 , and 15 weeks for @entity1487 ). Factors of liver @entity3 , adjacent anatomic involvement, time from initial diagnosis to study entry, and prior radiation were found to be significant determinants of survival. @entity632 did not appear to benefit @entity1 with advanced measurable squamous cell @entity189 . @entity1499 and @entity1487 showed comparable activity and survival, although @entity1499 was slightly more toxic.
